Wockhardt Limited (WOCKPHARMA) Net Income 2022–2026

Name: Wockhardt Limited (WOCKPHARMA) net income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Wockhardt Limited annual net income for fiscal 2026 was ₹2.1 billion, compared with -₹470 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

WOCKPHARMA Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	₹2.1B	(₹470M)	(₹4.6B)	(₹5.6B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WOCKPHARMA Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Net Income	₹1.1B	₹1.7B	₹590M	(₹900M)	(₹250M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

IPCALAB Net Income — Ipca Laboratories Limited
GLAND Net Income — Gland Pharma Limited
AJANTPHARM Net Income — Ajanta Pharma Limited
EMCURE Net Income — Emcure Pharmaceuticals Limited
1276 Net Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
NEULANDLAB Net Income — Neuland Laboratories Limited

More WOCKPHARMA metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All WOCKPHARMA financial statements → Interactive WOCKPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.